PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-12-31

Study Completion Date

2003-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this Phase I/II study are:

1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II.
2. To evaluate the hematopoietic and immunological responses after administering of PG2. Primarily to study the biological response of PG2, defined as WBC count in this study, and secondarily to study the immunological factors, IL-2, IL-6, TGF-beta, and G-CSF.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

NCT05440227

Cancer-related Fatigue

RECRUITING PHASE2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

NCT01238562

Chemotherapy Patients

COMPLETED PHASE1

Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor

NCT07096479

Chemotherapy-induced Neutropenia

RECRUITING

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

NCT00094809

Colon Cancer Colorectal Cancer Rectal Cancer

COMPLETED PHASE2

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

NCT01918241

Neutropenia

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is the first step for PG2 clinical development in Taiwan in order to further establish its safety and efficacy profile and to build the basis for larger trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasm Metastasis Neoplasm Recurrence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

125 mg/day Treatment Arm

125 mg/day PG2 treatment continuously for 7 days

Group Type EXPERIMENTAL

PG2

Intervention Type DRUG

Injectable

250 mg/day Treatment Arm

250 mg/day PG2 treatment continuously for 7 days

Group Type EXPERIMENTAL

PG2

Intervention Type DRUG

Injectable

500 mg/day Treatment Arm

500 mg/day PG2 treatment continuously for 7 days

Group Type EXPERIMENTAL

PG2

Intervention Type DRUG

Injectable

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PG2

Injectable

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must have malignancy with metastatic or recurrent diseases.
* Patient must have a minimum of thirteen days period elapsed from any previous chemotherapy or radiotherapy and all treatment-related toxicities subsided.
* Patient must have at least 2 courses of chemotherapy treatment left, and a minimum of 13 days between the administration of the last dose of the chemotherapy with PG2 and the start of the next course of chemotherapy.
* Performance status is 0-2 by ECOG scale.
* Patient's compliance and geographic proximity that allow adequate follow up.
* Adequate bone marrow function before the chemotherapy
* Adequate liver and renal function before the chemotherapy
* Written informed consent from patients
* Woman with childbearing potential should use contraception method through the whole PG2 treatment course.
* After the previous course of chemotherapy, the nadir of WBC dropped between 1000 to 3000/ mm3 (for phase II only).

Exclusion Criteria

* PG2 skin test is positive.
* Active infection
* Breast feeding
* Prior radiotherapy more than 30% of the bone marrow involved.
* Pregnant woman
* Bone marrow transplantation or brain disease

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No